Stock listing
Xetra:1RV Rhythm Pharmaceuticals, Inc. Aktie
German listing (Xetra) of Rhythm Pharmaceuticals, Inc. · home listing NASDAQ:RYTM
Follow Rhythm Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:RYTM
$112.36 USD -6.68 (-5.6%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RYTM
- Day range
- $112.00 – $117.01 USDNov 20, 2026
- Volume
- 1.50M sharesNov 20, 2026
- Market cap
- $7.79B USDAt the close on Nov 20, 2026 · price × 69.33M shares outstanding
- 52-week range
- $74.50 – $122.20 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $109.2M USDMedian day 644,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RYTM · Home | $112.36 USD | -6.68 (-5.6%) | 1,502,362 | $115.46 | $117.01 | $112.00 | $119.04 | Close on Nov 20, 2026 |
| Frankfurt:1RV | €100.00 EUR | -2.00 (-2.0%) | — | €105.00 | €105.00 | €100.00 | €102.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RYTM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $112.36 | -6.68 | -5.6% | $115.46 | $117.01 | $112.00 | 1,502,362 | |
| $119.04 | +2.43 | +2.1% | $115.72 | $121.41 | $114.59 | 2,014,530 | |
| $116.61 | +9.13 | +8.5% | $106.81 | $118.50 | $104.20 | 2,563,407 | |
| $107.48 | -7.54 | -6.6% | $113.23 | $114.93 | $107.21 | 947,267 | |
| $115.02 | +5.16 | +4.7% | $109.81 | $117.84 | $107.86 | 1,144,113 | |
| $109.86 | -2.30 | -2.1% | $112.26 | $112.26 | $108.94 | 1,054,918 | |
| $112.16 | -1.79 | -1.6% | $113.76 | $115.20 | $112.04 | 734,161 | |
| $113.95 | +0.01 | 0.0% | $113.42 | $115.06 | $112.51 | 616,028 | |
| $113.94 | +1.66 | +1.5% | $112.30 | $114.98 | $110.78 | 1,286,798 | |
| $112.28 | +7.26 | +6.9% | $107.10 | $113.29 | $104.31 | 4,928,737 | |
| $105.02 | -5.66 | -5.1% | $108.76 | $110.66 | $103.06 | 6,396,436 | |
| $110.68 | +24.24 | +28.0% | $85.94 | $110.68 | $85.04 | 5,489,582 | |
| $86.44 | -7.00 | -7.5% | $84.83 | $89.28 | $81.58 | 7,110,007 | |
| $93.44 | +0.87 | +0.9% | $93.13 | $95.35 | $92.40 | 2,003,953 | |
| $92.57 | -0.50 | -0.5% | $93.48 | $95.60 | $91.42 | 431,700 | |
| $93.07 | +1.10 | +1.2% | $93.00 | $94.16 | $92.52 | 760,500 | |
| $91.97 | -0.21 | -0.2% | $91.37 | $92.70 | $91.05 | 533,900 | |
| $92.18 | +2.71 | +3.0% | $89.36 | $92.72 | $88.72 | 400,200 | |
| $89.47 | +0.20 | +0.2% | $90.07 | $90.81 | $89.00 | 289,400 | |
| $89.27 | -1.63 | -1.8% | $90.44 | $90.44 | $88.56 | 536,900 | |
| $90.90 | +2.28 | +2.6% | $88.85 | $90.95 | $87.59 | 516,400 | |
| $88.62 | -1.58 | -1.8% | $91.02 | $92.18 | $88.12 | 511,300 | |
| $90.20 | +1.97 | +2.2% | $88.56 | $91.88 | $88.56 | 877,000 | |
| $88.23 | +2.06 | +2.4% | $87.04 | $88.76 | $86.59 | 378,800 | |
| $86.17 | -1.80 | -2.0% | $88.20 | $88.62 | $85.91 | 367,000 | |
| $87.97 | +1.26 | +1.5% | $88.41 | $90.42 | $87.61 | 644,600 | |
| $86.71 | +0.10 | +0.1% | $86.41 | $88.14 | $85.38 | 585,800 | |
| $86.61 | -3.21 | -3.6% | $89.63 | $90.51 | $86.35 | 623,000 | |
| $89.82 | -0.96 | -1.1% | $91.05 | $91.42 | $89.49 | 543,800 | |
| $90.78 | +1.14 | +1.3% | $89.67 | $93.35 | $89.41 | 1,411,400 | |
| $89.64 | +1.19 | +1.3% | $89.05 | $90.94 | $87.01 | 1,008,500 | |
| $88.45 | -2.32 | -2.6% | $90.77 | $91.37 | $88.23 | 939,400 | |
| $90.77 | -1.68 | -1.8% | $92.55 | $94.47 | $90.07 | 992,900 | |
| $92.45 | -0.38 | -0.4% | $93.95 | $94.41 | $89.53 | 1,027,200 | |
| $92.83 | -0.58 | -0.6% | $94.97 | $95.32 | $92.66 | 503,500 | |
| $93.41 | -1.805 | -1.9% | $95.34 | $96.48 | $93.00 | 850,600 | |
| $95.22 | -0.495 | -0.5% | $96.67 | $97.37 | $95.10 | 737,200 | |
| $95.71 | -2.85 | -2.9% | $97.92 | $98.91 | $94.51 | 810,900 | |
| $98.56 | -0.10 | -0.1% | $98.01 | $99.15 | $95.27 | 897,400 | |
| $98.66 | +0.35 | +0.4% | $98.41 | $99.45 | $96.35 | 864,300 | |
| $98.31 | +0.07 | +0.1% | $97.73 | $99.28 | $95.38 | 730,800 | |
| $98.24 | -1.03 | -1.0% | $99.27 | $100.02 | $96.47 | 696,400 | |
| $99.27 | +0.44 | +0.4% | $100.44 | $101.85 | $98.69 | 499,900 | |
| $98.83 | +1.12 | +1.1% | $98.47 | $100.76 | $97.54 | 613,600 | |
| $97.71 | -1.31 | -1.3% | $99.36 | $99.36 | $96.88 | 1,124,800 | |
| $99.02 | +1.01 | +1.0% | $101.17 | $102.00 | $98.80 | 617,700 | |
| $98.01 | +1.24 | +1.3% | $97.69 | $100.85 | $97.06 | 921,400 | |
| $96.77 | -5.67 | -5.5% | $101.66 | $101.66 | $96.14 | 914,300 | |
| $102.44 | -2.27 | -2.2% | $105.27 | $105.93 | $101.09 | 789,700 | |
| $104.71 | +2.51 | +2.5% | $102.96 | $106.57 | $102.25 | 573,700 | |
| $102.20 | +1.14 | +1.1% | $99.88 | $102.89 | $99.88 | 422,900 | |
| $101.06 | -0.74 | -0.7% | $100.23 | $101.77 | $99.83 | 478,600 | |
| $101.80 | -0.94 | -0.9% | $100.58 | $103.31 | $99.41 | 513,000 | |
| $102.74 | -2.15 | -2.0% | $103.53 | $105.71 | $101.25 | 466,900 | |
| $104.89 | -0.53 | -0.5% | $106.08 | $106.08 | $103.90 | 269,800 | |
| $105.42 | +0.68 | +0.6% | $105.50 | $108.57 | $103.95 | 455,600 | |
| $104.74 | -1.39 | -1.3% | $105.79 | $108.43 | $104.09 | 332,000 | |
| $106.13 | -1.04 | -1.0% | $106.01 | $108.85 | $103.98 | 775,200 | |
| $107.17 | -5.36 | -4.8% | $110.21 | $114.75 | $107.09 | 441,200 | |
| $112.53 | +0.66 | +0.6% | $111.21 | $113.97 | $110.03 | 311,100 | |
| $111.87 | -1.48 | -1.3% | $113.21 | $114.75 | $111.35 | 359,000 | |
| $113.35 | +1.91 | +1.7% | $112.73 | $114.07 | $111.79 | 352,500 | |
| $111.44 | +1.44 | +1.3% | $112.29 | $113.60 | $109.89 | 400,600 | |
| $110.00 | +1.08 | +1.0% | $109.38 | $112.59 | $106.58 | 523,100 | |
| $108.92 | -6.81 | -5.9% | $114.51 | $114.61 | $108.73 | 568,600 |
- Ticker
- Xetra:1RV
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Xetra
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
Latest earnings call · Nov 3, 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 3, 2026
Q3 2026 Earnings Presentation
Earnings · 29 slides
Latest news
Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
Nov 16, 2026
Closed $116.61 (+8.5%) on Nov 17, 2026
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome
Nov 4, 2026
Closed $110.68 (+28.0%) on Nov 4, 2026
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update
Nov 3, 2026
Closed $86.44 (-7.5%) on Nov 3, 2026
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
Nov 2, 2026
Closed $86.44 (-7.5%) on Nov 3, 2026
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Oct 21, 2026
Closed $88.62 (-1.8%) on Oct 21, 2026
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
Oct 13, 2026
Closed $86.71 (+0.1%) on Oct 14, 2026
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
Sep 22, 2026
Closed $99.27 (+0.4%) on Sep 22, 2026
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
Sep 10, 2026
Closed $102.20 (+1.1%) on Sep 10, 2026
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
Aug 24, 2026
Closed $111.44 (+1.3%) on Aug 24, 2026
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
Aug 17, 2026
Closed $115.44 (0.0%) on Aug 17, 2026
Rhythm Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 37 in the last 12 months · 225 in all · newest Nov 16, 2026 · oldest 2019
- Calls
- 22 calls with a replay · 22 with a transcript · latest Nov 3, 2026
- Decks
- 61 decks · latest Nov 3, 2026
Where Rhythm Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RYTM · Home listing | NASDAQ | United States | USD |
| LS Exchange:A2H5A0 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2H5A0 | Lang & Schwarz | Germany | EUR |
| gettex:1RV | gettex | Germany | EUR |
| Tradegate:1RV | Tradegate | Germany | EUR |
| BMV:RYTM | BMV | Mexico | MXN |
| BOATS:RYTM | BOATS | United States | USD |
| Frankfurt:1RV | Frankfurt | Germany | EUR |
| BIVA:RYTM | BIVA | Mexico | MXN |
| Dusseldorf:1RV | Dusseldorf | Germany | EUR |
| Munich:1RV | Munich | Germany | EUR |
| Stuttgart:1RV | Stuttgart | Germany | EUR |
| Xetra:1RV · This page | Xetra | Germany | EUR |
Valuation
EV/sales 27.0× against a median of 4.4×: the highest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $7.57B USD
- P/E
- Loss
- EV/sales
- 27.0×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 88.6×
- Gross margin
- 88.2%
- Operating margin
- −66.7%
- Net margin
- −69.0%
- Debt to equity
- 1.2×
- Beta vs S&P 500
- 1.20
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. · NASDAQ:RYTM | US$7.79B | US$7.57B | n/a | 27.0× | n/a | 88.6× | −69.0% | 1.2× | 1.20 |
| Haisco Pharmaceutical Group Co. Ltd. Class A · SZSE:002653 | US$8.97B | US$8.66B | 44.7× | 9.5× | n/a | 10.1× | 22.1% | 0.1× | n/a |
| Madrigal Pharmaceuticals, Inc. · NASDAQ:MDGL | US$8.81B | US$8.19B | n/a | 5.7× | n/a | 14.1× | −10.9% | 0.5× | 0.50 |
| Glenmark Pharmaceuticals Limited · NSE:GLENMARK | US$8.06B | US$8.05B | 51.5× | 4.7× | 22.6× | 6.7× | 9.2% | 0.1× | n/a |
| Amneal Pharmaceuticals, Inc. · NASDAQ:AMRX | US$7.36B | US$10.14B | 55.2× | 3.2× | 16.0× | 13.8× | 4.2% | 5.5× | 0.67 |
| Chemical Works of Gedeon Richter PLC · BET:RICHTER | US$7.13B | US$6.29B | 10.4× | 2.3× | 5.6× | 1.8× | 25.0% | 0.0× | n/a |
| ALK-abello A/S Class B · OMXCOP:ALK_B | US$7.07B | US$6.82B | 34.3× | 6.6× | 20.9× | 6.6× | 19.9% | 0.1× | n/a |
| Corcept Therapeutics Incorporated · NASDAQ:CORT | US$6.88B | US$6.52B | 42.4× | 6.8× | 57.2× | 8.3× | 16.8% | 0.0× | 1.59 |
| Alkem Laboratories Ltd. · NSE:ALKEM | US$6.69B | US$6.78B | 30.0× | 4.0× | 20.0× | 4.2× | 13.2% | 0.2× | n/a |
| Huadong Medicine Co., Ltd. Class A · SZSE:000963 | US$6.53B | US$5.95B | 12.7× | 0.9× | n/a | 1.7× | 7.8% | 0.0× | n/a |
| China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A · SZSE:000999 | US$6.48B | US$5.85B | 13.4× | 1.3× | n/a | 1.9× | 10.4% | 0.1× | n/a |
| Median of the others | US$7.10B | US$6.80B | 34.3× | 4.4× | 20.5× | 6.7× | 11.8% | 0.1× | 0.67 |
Forecasts
12 strong buy · 5 buy · 2 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 140.12 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.94 · 14 analysts
- Revenue, year to Dec 2026
- 330.6M · 17 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| David Meeker | Chairman, President, and Chief Executive Officer |
| Hunter Smith | Chief Financial Officer and Treasurer |
| Jim Flaherty | Senior Vice President and General Counsel |
| Elisabeth Crönert-Bendell | Senior Vice President, Head of Strategy |
| Jennifer Lee | Executive Vice President, Head of North America |
| Yann Mazabraud | Executive Vice President, Head of International |
| Alastair Garfield | Chief Scientific Officer |
| Alicia Fiscus | Chief Regulatory Officer |
| Joe Shulman | Chief Technical Officer |
| Manher AJ Joshi | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| David Meeker | Chairman, President, and Chief Executive Officer |
| Christophe R. Jean | Director |
| David McGirr | Director |
| Jennifer Good | Director |
| Kimberly J. Popovits | Director |
| Lynn Tetrault | Director |
| Stuart Arbuckle | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2026 Earnings Call | Tue, Nov 03, 2026 · 8:00 AM ET | Replay |
| Rhythm Pharmaceuticals (NASDAQ:RYTM) Q2 2026 Earnings Call | Tue, Aug 04, 2026 · 8:00 AM ET | Replay |
| Rhythm Pharmaceuticals (NASDAQ:RYTM) Q1 2026 Earnings Call | Tue, May 05, 2026 · 8:00 AM ET | Replay |
| Rhythm Pharmaceuticals (NASDAQ:RYTM) Q4 2025 Earnings Call | Thu, Feb 26, 2026 · 8:00 AM ET | Replay |
| Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2025 Earnings Call | Tue, Nov 04, 2025 · 8:00 AM ET | Replay |
| Rhythm Pharmaceuticals (NASDAQ:RYTM) Q2 2025 Earnings Call | Tue, Aug 05, 2025 · 8:00 AM ET | Replay |
| Rhythm Pharmaceuticals (NASDAQ:RYTM) Q1 2025 Earnings Call | Wed, May 07, 2025 · 8:00 AM ET | Replay |
| Rhythm Pharmaceuticals (NASDAQ:RYTM) Q4 2024 Earnings Call | Wed, Feb 26, 2025 · 8:00 AM ET | Replay |
| Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2024 Earnings Call | Tue, Nov 05, 2024 · 5:00 PM ET | Replay |
| Rhythm Pharmaceuticals (NASDAQ:RYTM) Q2 2024 Earnings Call | Tue, Aug 06, 2024 · 8:00 AM ET | Replay |
All 22 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · Before open | −7.5% |
| Q2 2026 | Aug 4, 2026 · Before open | +2.9% |
| Q1 2026 | May 5, 2026 · Before open | +7.9% |
| Q4 2025 | Feb 26, 2026 | −6.5% |
| Q3 2025 | Nov 4, 2025 · Before open | −7.7% |
| Q2 2025 | Aug 5, 2025 · Before open | −1.9% |
| Q1 2025 | May 7, 2025 · Before open | +3.1% |
| Q4 2024 | Feb 20, 2025 · Before open | −0.5% |
| Q3 2024 | Nov 5, 2024 · After close | +11.4% |
| Q2 2024 | Aug 6, 2024 · Before open | +0.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · Before open | −10.3% |
| Q4 2023 | Feb 22, 2024 · Before open | −9.7% |
| Q3 2023 | Nov 7, 2023 · Before open | −0.5% |
| Q2 2023 | Aug 1, 2023 · Before open | +27.5% |
| Q1 2023 | May 2, 2023 · Before open | −7.3% |
| Q4 2022 | Mar 1, 2023 · Before open | +6.3% |
| Q3 2022 | Nov 8, 2022 · Before open | +2.5% |
| Q2 2022 | Aug 2, 2022 · Before open | +13.8% |
| Q1 2022 | May 3, 2022 · Before open | −2.7% |
| Q4 2021 | Mar 1, 2022 · Before open | +11.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 29 slides | Nov 3, 2026 |
| 64th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) 2026 | Conference | 16 slides | September 2026 |
| 64th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) 2026 | Conference | 13 slides | September 2026 |
| Investor Presentation (September 2026) | Investor deck | 66 slides | September 2026 |
| Q2 2026 Earnings Presentation | Earnings | 31 slides | Aug 4, 2026 |
| ENDO 2026 | Conference | 26 slides | Jun 15, 2026 |
| ENDO 2026 | Conference | 26 slides | Jun 13, 2026 |
| Investor Presentation (June 2026) | Investor deck | 52 slides | June 2026 |
| Q1 2026 Earnings Presentation | Earnings | 23 slides | May 5, 2026 |
| Investor Presentation (April 2026) | Investor deck | 50 slides | April 2026 |
Show 50 decks
This page holds 50 of 61 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Made bigger: about US$175M · US$85 a share · Morgan Stanley +5 Dealers: Morgan Stanley (co-lead), BofA Securities (co-lead), Stifel (co-lead), Wells Fargo Securities (co-lead), Canaccord Genuity, Citizens Capital Markets | Jul 10, 2025 |
| At-the-market programme of common stock Closed: US$75M raised · US$56.3 a share | Feb 26, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$17.00 a share on Oct 4, 2017.
- Price
- US$17.00 a share
- Shares offered
- 7,050,000 shares of common stock
- Offering size
- US$119.8 million
- Underwriters' option
- Up to 1,057,500 more shares
- Listing
- RYTM on the Nasdaq Global Market
- Underwriters
- MORGAN STANLEY, BofA MERRILL LYNCH, COWEN, NEEDHAM & COMPANY · In the order on the cover
- Shares delivered
- On or about Oct 10, 2017
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 13, 2015 |
| Filed publicly | Sep 5, 2017 |
| Amended once | Sep 25, 2017 |
| Shares registered with an exchange | Sep 29, 2017 |
| Declared effective by the SEC | Oct 4, 2017 |
| Final prospectus, with the price | Oct 5, 2017 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 5, 2017 |
| EFFECT · Notice that a registration is effective | Oct 4, 2017 |
| S-1MEF · Registration of more shares for the same offering | Oct 4, 2017 |
| CERTNAS · Nasdaq's certificate of listing | Oct 3, 2017 |
| CORRESP · Letter to the SEC | Oct 2, 2017 |
| CORRESP · Letter to the SEC | Oct 2, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 29, 2017 |
| CORRESP · Letter to the SEC | Sep 27, 2017 |
| CORRESP · Letter to the SEC | Sep 27, 2017 |
| S-1/A · Registration statement, amended | Sep 25, 2017 |
All 25 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Sep 18, 2017 |
| S-1 · Registration statement | Sep 5, 2017 |
| DRSLTR · Letter to the SEC with a draft | Aug 23, 2017 |
| DRS/A · Draft registration statement, amended | Aug 23, 2017 |
| UPLOAD · Letter from the SEC | Jun 21, 2017 |
| DRS/A · Draft registration statement, amended | May 24, 2017 |
| DRSLTR · Letter to the SEC with a draft | May 23, 2017 |
| UPLOAD · Letter from the SEC | May 3, 2016 |
| DRSLTR · Letter to the SEC with a draft | Apr 6, 2016 |
| DRS/A · Draft registration statement, amended | Apr 6, 2016 |
| UPLOAD · Letter from the SEC | Dec 23, 2015 |
| DRSLTR · Letter to the SEC with a draft | Dec 9, 2015 |
| DRS/A · Draft registration statement, amended | Dec 9, 2015 |
| UPLOAD · Letter from the SEC | Nov 10, 2015 |
| DRS · Draft registration statement | Oct 13, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 5, 2017
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 189.8M | 130.1M | 77.4M | 23.6M | 3.15M | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 19.5M | 13.4M | 9.30M | 2.13M | 599.0K | 690.0K | 834.0K | 442.0K | 223.0K | 144.0K |
| Gross profit | 170.3M | 116.8M | 68.1M | 21.5M | 2.56M | -690.0K | -834.0K | -442.0K | -223.0K | -144.0K |
| Research and development | 167.3M | 238.0M | 135.0M | 108.6M | 104.1M | 90.5M | 109.5M | 50.3M | 22.9M | 19.6M |
| Selling, general and administrative | 194.9M | 144.3M | 117.5M | 92.0M | 68.5M | 46.1M | 36.5M | 28.1M | 9.52M | 6.31M |
| Operating income | -192.0M | -265.5M | -184.4M | -179.2M | -170.1M | -136.6M | -146.0M | -78.4M | -32.4M | -25.9M |
| Depreciation and amortization | 500.0K | 700.0K | 900.0K | 896.0K | 816.0K | 690.0K | 834.0K | 442.0K | 223.0K | 144.0K |
| EBITDA | -191.5M | -264.8M | -183.5M | -178.3M | -169.2M | -135.9M | -145.2M | -78.0M | -32.2M | -25.8M |
| Interest expense | 20.6M | 20.6M | 13.9M | 5.20M | 100.4M | 0 | 0 | 0 | 0 | 0 |
| Income before tax | -196.0M | -260.3M | -184.1M | -181.1M | -69.6M | -134.0M | -140.7M | -74.1M | -33.7M | -25.9M |
| Income tax | 497.0K | 346.0K | 564.0K | 1.96M | -1.60M | -3.27M | -6.11M | 4.35M | 1.07M | 0 |
| Net income | -196.5M | -260.6M | -184.7M | -181.1M | -69.6M | -134.0M | -140.7M | -74.1M | -33.7M | -29.1M |
| Earnings per share, basic | -3.11 | -4.34 | -3.20 | -3.47 | -1.40 | -3.04 | -3.86 | -2.39 | -2.83 | -2.85 |
| Earnings per share, diluted | -3.11 | -4.34 | -3.20 | -3.47 | -1.40 | -3.04 | -3.86 | -2.39 | -2.83 | -2.85 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 54.3M | 89.1M | 60.1M | 127.7M | 59.2M | 100.9M | 62.3M | 49.5M | 34.2M | 6.54M |
| Short-term investments | 334.6M | 231.4M | 215.8M | 205.6M | 235.6M | 71.9M | 230.2M | 202.5M | 113.8M | 4.00M |
| Receivables | 26.1M | 18.5M | 14.9M | 6.22M | 1.02M | 0 | ||||
| Inventory | 25.8M | 18.7M | 8.62M | 2.92M | 111.0K | 0 | ||||
| Current assets | 466.9M | 374.2M | 308.3M | 354.2M | 308.4M | 181.7M | 302.4M | 258.7M | 150.7M | 11.2M |
| Property, plant and equipment | 1.10M | 632.0K | 1.34M | 2.20M | 2.81M | 3.19M | 3.67M | 1.12M | 840.0K | 930.0K |
| Goodwill | 0 | |||||||||
| Total assets | 480.2M | 392.3M | 332.7M | 382.5M | 329.5M | 187.1M | 308.5M | 260.2M | 151.7M | 12.3M |
| Accounts payable | 13.9M | 12.3M | 4.88M | 4.80M | 5.74M | 4.90M | 10.4M | 7.64M | 2.43M | 1.90M |
| Current liabilities | 105.9M | 115.5M | 55.2M | 39.8M | 43.4M | 18.0M | 24.4M | 13.6M | 6.72M | 4.73M |
| Long-term debt | 100.9M | 108.3M | 106.1M | 1.34M | 0 | |||||
| Total debt | 108.2M | 109.8M | 106.1M | 2.02M | 2.55M | 3.09M | 3.56M | |||
| Total liabilities | 210.2M | 227.7M | 163.0M | 118.2M | 45.4M | 20.5M | 27.5M | 14.0M | 6.95M | 5.04M |
| Shareholders' equity | 139.1M | 21.7M | 169.8M | 264.3M | 284.2M | 166.5M | 281.0M | 246.3M | 144.8M | -32.7M |
| Shares outstanding | 67.2M | 62.4M | 59.4M | 56.6M | 50.3M | 44.2M | 44.0M | 34.4M | 27.3M | 10.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -115.7M | -113.9M | -136.2M | -173.4M | -146.0M | -122.0M | -122.8M | -62.1M | -29.5M | -23.2M |
| Capital spending | -953.0K | 0 | -47.0K | -281.0K | -434.0K | -214.0K | -3.38M | -722.0K | -133.0K | -1.06M |
| Free cash flow | -116.6M | -113.9M | -136.2M | -173.7M | -146.4M | -122.2M | -126.1M | -62.8M | -29.6M | -24.3M |
| Cash from investing | -137.2M | -48.2M | -5.67M | 28.0M | -62.2M | 158.5M | -28.0M | -87.1M | -110.0M | -5.11M |
| Cash from financing | 218.0M | 191.2M | 74.4M | 213.8M | 166.5M | 2.01M | 163.5M | 164.7M | 167.2M | 0 |
| Dividends paid | -5.38M | -3.97M | 0 | |||||||
| Share buybacks | 141.5M | 166.5M | 2.01M | 163.5M | 164.7M | 167.2M | 126.4M | |||
| Change in cash | -34.8M | 29.2M | -67.6M | 68.4M | -41.7M | 38.6M | 12.8M | 15.5M | 27.7M | -28.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 10, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 25, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 15, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | May 29, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | May 5, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | May 5, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 3, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 26, 2026 | Current report | SEC |
| 8-K · Current report | Mar 20, 2026 | Current report | SEC |
| 8-K · Current report | Mar 16, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 2, 2026 | Current report | SEC |
| S-3ASR · Registration statement | Feb 26, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Jan 16, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 9, 2026 | Results | SEC |
| 8-K · Current report | Dec 19, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 11, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 11, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 7, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 7, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 30, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 11, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 11, 2025 | Current report | SEC |
| 424B5 · Prospectus | Jul 10, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jul 9, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 9, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Jul 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 30, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 29, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 24, 2025 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 8, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 7, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 20, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 14, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 28, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 28, 2025 | Current report | SEC |
| 10-K · Annual report | Feb 28, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
This page holds 200 of 841 filings. Open Filings
Cap table
Built by 6ix from Rhythm Pharmaceuticals, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 69,330,906
- Fully diluted
- 69,330,906
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 69,330,906 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 69,330,906 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Edward Mathers Other companies: NeueHealth Inc (Director · Since at least Oct 2, 2025); MBX Biosciences, Inc. (Director · Since at least Sep 12, 2024); Senti Biosciences Holdings, Inc. (Director · Since at least Jun 8, 2022); OnKure Therapeutics, Inc. (Director · Since at least Apr 8, 2021); Trevi Therapeutics, Inc. (Director · Since at least May 7, 2019); Inozyme Pharma Inc (Director · Jul 23, 2020 – Jun 18, 2024 · Past); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Mirum Pharmaceuticals, Inc. (Director · Jul 17, 2019 – Jun 2, 2022 · Past); Ra Pharmaceuticals Inc (Director · Jun 28, 2018 – Apr 2, 2020 · Past); Synlogic Inc (Director · Dec 29, 2017 – Jun 22, 2023 · Past) | Director · Since at least Oct 4, 2017 |
| Kimberly Popovits Other companies: Kardigan, Inc. (Director · Since at least Jun 17, 2026); EXACT Sciences Corporation (Director · Since at least Jan 2, 2025); 10x Genomics, Inc. (Director · Since at least Mar 26, 2020); Kiniksa Pharmaceuticals International, plc (Director · Since at least May 23, 2018); Talis Biomedical Corp (Director · Feb 11, 2021 – Jun 9, 2023 · Past); MyoKardia Inc (Director · Mar 15, 2017 – Nov 17, 2020 · Past); Genomic Health Inc (President and CEO, Director · Nov 3, 2016 – Nov 8, 2019 · Past) | Director · Since at least Apr 1, 2026 |
| David Meeker Other companies: Kardigan, Inc. (Board of Directors · Since at least Jun 17, 2026); Pharvaris N.V. (Chair of the Board · Since at least Mar 18, 2026); Trevi Therapeutics, Inc. (Chairman · Since at least May 7, 2019); Turmeric Acquisition Corp (Director · Oct 15, 2020 – Oct 15, 2020 · Past); MyoKardia Inc (Director · Apr 17, 2017 – Nov 17, 2020 · Past); Savient Pharmaceuticals Inc (Director · Jan 7, 2013 – Jan 7, 2013 · Past) | Chairman, President, and Chief Executive Officer · Since at least Oct 4, 2017 |
| David McGirr Other companies: X4 Pharmaceuticals, Inc. (Director · Since at least Nov 15, 2017); Insmed Incorporated (Director · Since at least Oct 30, 2013); Roka Bioscience Inc (Director · Jul 16, 2014 – Jun 28, 2017 · Past); Relypsa Inc (Director · Nov 14, 2013 – Sep 1, 2016 · Past); Cubist Pharmaceuticals Inc (SVP & Chief Financial Officer · Mar 31, 2010 – Feb 15, 2013 · Past) | Director · Since at least Oct 4, 2017 |
| Neil Exter Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Decibel Therapeutics Inc (Director · Feb 11, 2021 – Jun 17, 2022 · Past); Pliant Therapeutics, Inc. (Director · Jun 2, 2020 – Jun 16, 2022 · Past); Revolution Medicines, Inc. (Director · Feb 12, 2020 – Jun 16, 2022 · Past); CytomX Therapeutics, Inc. (Director · Oct 7, 2015 – Jun 20, 2017 · Past) | Director · Oct 4, 2017 – Jun 6, 2018 · Past |
| Stuart Arbuckle Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Jan 8, 2026); Alnylam Pharmaceuticals, Inc. (Director · Since at least Jan 5, 2026); Vertex Pharmaceuticals Incorporated (EVP, COO · Since at least May 25, 2016); ImmunoGen Inc (Director · Jan 23, 2018 – Feb 12, 2024 · Past); Dare Bioscience, Inc. (Director · Jun 22, 2016 – Jan 3, 2017 · Past) | Director · Since at least Jul 23, 2019 |
| Jonathan Silverstein Other companies: Arcutis Biotherapeutics, Inc. (Director · Jan 30, 2020 – Oct 2, 2020 · Past); Adicet Bio, Inc. (Director · Jan 25, 2018 – Jun 3, 2020 · Past); Glaukos Corporation (Director · Dec 13, 2017 – Mar 2, 2018 · Past); Scpharmaceuticals Inc (Director · Nov 16, 2017 – Nov 21, 2017 · Past) | Director · Oct 4, 2017 – Oct 4, 2017 · Past |
| Jennifer Good Other companies: Trevi Therapeutics, Inc. (President and Chief Executive Officer · Since at least May 7, 2019); Juniper Pharmaceuticals Inc (Director · Sep 7, 2017 – Aug 14, 2018 · Past); Penwest Pharmaceuticals Co (President & CEO · Apr 28, 2010 – Nov 4, 2010 · Past) | Director · Since at least Jun 19, 2019 |
| Keith Gottesdiener Other companies: Septerna, Inc. (Director · Since at least Sep 25, 2025); Prime Medicine, Inc. (See Remarks, Director · Oct 19, 2022 – May 8, 2025 · Past); Intercept Pharmaceuticals Inc (Director · Jul 19, 2016 – Nov 8, 2023 · Past) | CEO & President, Director · Oct 4, 2017 – Mar 9, 2020 · Past |
| Lynn A. Tetrault Other companies: Alumis Inc. (Director · Since at least May 21, 2025); NeoGenomics, Inc. (Director · Since at least Jun 2, 2021); Acelyrin, Inc. (Director · Dec 18, 2023 – May 21, 2025 · Past) | Director · Since at least Dec 9, 2020 |
All 24 people
| Person | Seat |
|---|---|
| Camille L. Bedrosian Other companies: Crinetics Pharmaceuticals, Inc. (Director · Since at least Jun 11, 2025); Amylyx Pharmaceuticals, Inc. (Chief Medical Officer · Since at least Mar 31, 2025) | Director · Since at least Jun 18, 2025 |
| Hunter Smith Other companies: Spyre Therapeutics, Inc. (Director · Nov 12, 2021 – Jun 22, 2023 · Past); Genesee & Wyoming Inc (Director · Jun 30, 2015 – Dec 30, 2019 · Past) | Chief Financial Officer and Treasurer · Since at least Oct 4, 2017 |
| Fred T Fiedorek Other companies: Verve Therapeutics Inc (Chief Medical Officer · Sep 18, 2023 – Feb 14, 2024 · Past) | Chief Medical Officer · Oct 4, 2017 – Feb 14, 2018 · Past |
| Jennifer Chien Other companies: Krystal Biotech, Inc. (Chief Commercial Officer · Jan 20, 2020 – Jan 31, 2020 · Past) | EVP, Head of North America · Since at least Nov 9, 2020 |
| Alastair Garfield | Chief Scientific Officer · Since at least Jul 1, 2025 |
| Alicia Fiscus | Chief Regulatory Officer · Since at least Nov 5, 2026 |
| Christophe R. Jean | Director · Since at least Jun 18, 2025 |
| Christopher Paul German | Corporate Controller & CAO · Since at least Aug 11, 2023 |
| Elisabeth Crönert-Bendell | Senior Vice President, Head of Strategy · Since at least Nov 5, 2026 |
| Jennifer Lee | Executive Vice President, Head of North America · Since at least Aug 14, 2026 |
| Jim Flaherty | Senior Vice President and General Counsel · Since at least Nov 5, 2026 |
| Joe Shulman | Chief Technical Officer · Since at least Jul 9, 2025 |
| Manher Joshi | Chief Medical Officer · Since at least Aug 17, 2026 |
| Yann Mazabraud | EVP, Head of International · Since at least Oct 5, 2020 |
Log in to ask 6ix AI your own questions about Rhythm Pharmaceuticals, Inc.